 |
8 Diseases |  |
17 Trials |
|
17 Trials |  |
2602 News |  |
| «12...678910111213141516...2425» |
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] COVID-19 severity and mortality in multiple sclerosis do not depend on immunotherapy: insights from a nation-wide Austrian Registry (Stream 1 Clinical) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1173;
In a population-based MS cohort, COVID-19 severity and mortality were independent of exposure to DMT and immunosuppressive DMT when accounting for other already known risk factors. This provides reassuring evidence that COVID-19 risk can be individually anticipated in MS and – except for a very small proportion of high-risk patients – treatment decisions should be focused on treating MS rather than the pandemic.
- Zinbryta (daclizumab) / Biogen, AbbVie
[VIRTUAL] Blueteq data : EDSS scores in patients on disease modifying therapy at a single centre (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1068;
These results present real world data on the use of EDSS to monitor response to treatment. The Blueteq data is currently limited by a short length of follow up but has potential value over time in tracking mean change in EDSS on each DMT.
- Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Long-term immune-related adverse events after alemtuzumab (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1065;
The autoimmune adverse events are probably related to immune dysregulation due to a differential lymphocyte repopulation following alemtuzumab. Autoimmune adverse events may be frequent, and it would be recommended to monitor its appearance in order to diagnose and treat them.
- Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of alemtuzumab (IMSE 3) (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1055;
Patients treated with ALZ for at least 48 months improved or remained stable across all effectiveness measures. Continued follow-up is needed to evaluate the real-world effectiveness and safety of ALZ.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] The effect of alemtuzumab treatment in relapsing remitting multiple sclerosis: real-world data from a five-year prospective one center study (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1053;
This real-world population confirms that ALZ as mostly second- or third-line treatment effectively reduced disease activity. Although most of our patients had previously failed on DMT the proportion of progression free survival (76%) and cumulative NEDA-3 (33%) were of similar magnitude as those reported from the extensions studies of the pivotal trials CARE-MS I II.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Alemtuzumab maintains efficacy on clinical and MRI disease activity outcomes, including slowing of brain volume loss, over 10 years in RRMS patients: CARE-MS I follow-up (TOPAZ Study) (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1052;
P3, P4
Efficacy of alemtuzumab on clinical, MRI lesion, and brain volume outcomes was maintained over 10 y in CARE-MS I patients, with 73% remaining on study and 53% receiving no additional courses or other DMTs through Y10. No delayed safety signal was evident over 10 y; AE incidences consistently declined over time, including a sustained reduction in autoimmune AE occurrence after Y3.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Efficacy of highly active disease modifying treatment versus interferon in multiple sclerosis: a UK MS register study (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1049;
However, HA-DMTs show a significant improvement in EDSS over NT for 1.0-point change and over ΒIFN for a 0.5 change. Whilst neither ΒIFN nor HA-DMTs delayed worsening of the EDSS compared to NT.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Early treatment with alemtuzumab maintains its efficacy on clinical and MRI disease activity outcomes, including slowing of brain volume loss, over 10 years in RRMS patients: CARE-MS II follow-up (TOPAZ Study) (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1041;
P3, P4
Early treatment efficacy with alemtuzumab on clinical, MRI lesion, and brain volume outcomes was maintained over 10 y in CARE-MS II patients, with 62% remaining on study and 39% receiving no additional courses or other DMTs through Y10. Safety remained consistent and manageable over 10 y, with declining AE incidences over time, including a consistent reduction in autoimmune AE occurrence after Y3.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Real-world patient-reported outcomes in RRMS patients transitioning to alemtuzumab: results from the PRO-ACT study (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1024;
Significant improvements in employment and household productivity were seen after switching, which may reflect a reduction in the burden that MS imposes on patients with employment and household responsibilities. Alemtuzumab safety was consistent with the pivotal studies.
- Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Hemophagocytic lymphohistiocytosis and alemtuzumab: a rescue or a cause? (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_922;
Albeit rarely, HLH can be triggered by ALM treatment for various diseases, such as HA-RRMS. Neurologists should be aware of this potentially lethal condition which can favourably respond to prompt immunosuppressant therapy.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] COVID-19 (inactivated and mRNA) vaccine and humoral response in people with multiple sclerosis: Chilean cohort (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_907;
In our cohort, most of the treatments are likely to produce humoral response to the COVID-19 vaccine, especially alemtuzumab, cladribine and natalizumab, regardless the infusion/administration time. Further study needs to be done that includes more patients with antiCD20 and fingolimod but also it is important that the studies take into consideration the type of vaccine (T cell dependent response), B cell reconstitution and lymphocyte subpopulations for B and T cells.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Additional courses of alemtuzumab in sub-optimal responder multiple sclerosis patients are safe and effective: experience from 15 Italian MS centers (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_902;
Further study needs to be done that includes more patients with antiCD20 and fingolimod but also it is important that the studies take into consideration the type of vaccine (T cell dependent response), B cell reconstitution and lymphocyte subpopulations for B and T cells. Despite the limitations of a retrospective study and the small number of patients, our study confirms that additional ALZ courses in MS are safe and can effectively lengthen control of disease activity, representing a valid option for patients with a sub-optimal therapeutic response.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] A retrospective review of COVID spike protein antibody development following COVID-19 vaccination in MS patients on disease modifying drugs (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_889;
This study is limited in retrospective design, small un-balanced groups, and lack of longitudinal data. We cannot exclude the possibility of a more robust delayed humoral response.
- Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Alemtuzumab-related lymphocytes subset dynamics and disease activity or autoimmune adverse event (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_888;
We found a potential association between CD8 lymphocytes and clinical relapses. A longer follow up could better define the possible role of lymphocyte subsets in predicting disease reactivation.
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Treatment of multiple sclerosis with Rituximab: a multicenter Spanish experience (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_877;
Rituximab could be an effective and safe treatment in RRMS, including aggressive forms of the disease. Some selected PMS patients could also benefit from this treatment.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] IgG immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within MS PATHS (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_876;
Quantifying post-vaccination IgG response across DMTs is crucial to optimize MS management. Data from ongoing sample collection will be presented at the meeting.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Humoral and cellular immune responses to SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_874;
Preliminary results show altered protective humoral immunity in MS patients treated with rituximab and fingolimod. Continuous analysis of cellular immunity is conducted in these patients.
- Actemra IV (tocilizumab) / Roche, JW Pharma, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] COVID-19 in patients with multiple sclerosis and neuromyelitis optica spectrum disorder in Colombia (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_838;
No significant differences were observed by sex and treatment type in prognosis and mortality from COVID-19. However, we suggested to carry out robust sample studies to identify the main complicating factors and severity.
- Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Efficacy and safety of alemtuzumab in clinical practice in Northeastern Spain (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_798;
Infusion related adverse events are frequent but mild. However, monitoring is crucial to detect serious infectious or autoimmune adverse events.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] REALMS Study: Single-center retrospective observational single-center study of alemtuzumab (Lemtrada®) treatment in a Spanish cohort of multiple sclerosis patients under real-life conditions (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_796;
Alemtuzumab was found a very effective therapy in our cohort, as the 48,8% reached a 6 months CDI and the mean of number of relapses decreased from 1,5 to 0,1. We believe it is an effective drug that should be used in the right patient knowing its safety profile.
- Mavenclad (cladribine) / EMD Serono
[VIRTUAL] Cladribine in a real world setting. The real patients (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_790;
23 patients switch from teriflunomide, 16 from dimethylfumarate, 14 from fingolimod, 22 from injectables, 1 from alemtuzumab... In the real world cladribine has proved to be effective, safe and very well tolerated.
- Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Higher prevalence of spinal cord relapses after treatment with alemtuzumab (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_789;
After a mean of more than 2 years of follow up, the 90,2% of our patients has not needed to be retreated with additional courses of alemtuzumab. Although the relapse rate after ALZ is very low, we´ve observed a higher prevalence (75%) of spinal cord relapses and this data is not describe in literature.
- Campath (alemtuzumab) / Sanofi, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Real-world evidence of immune reconstitution therapies: use of Cladribine and Alemtuzumab in Chile (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_773;
Special concerns are raised in patients switching from fingolimod to CLAD. Infections seem equivalent in both groups, while more patients developed secondary autoimmunity after ALEM.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] MASTER-2 trial: cladribine tablets in patients with relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis after suboptimal response to prior infusion/oral disease-modifying therapy (interim baseline results) (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_772;
P=N/A
MASTER-2 will report real-world data on the effects of CladT3.5 after a suboptimal response to oral/infusion DMT. Baseline analysis is ongoing and results from a data cut in July 2021 will be shown in the presentation.
- Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Anti-Spike IgG after BNT162b2 vaccine in a group of multiple sclerosis patients from an exploratory case-control study in Italy (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_757;
In our study, most MS patients produce a serological response to BNT162b2 similar to non-MS controls; however, at-risk DMTs resulted in reduced anti-Spike levels and one ocrelizumab-treated patient did not respond. These observations should be better investigated and replicated in larger studies to support clinical decision in COVID-19 vaccine management.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Effectiveness and safety of early high-efficacy vs. escalation therapy in relapsing-remitting multiple sclerosis in Argentina (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_748;
Our study shows that EHE therapies prevent disease progression, relapses and new MRI lesions and demonstrated no increased risk of specific adverse events when compared to ES therapy. This data should be considered when selecting a specific treatment for MS patients.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Real-world effectiveness of alemtuzumab in RRMS patients in Germany: Interim results of the TREAT-MS study after completion of recruitment (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_737;
The current results indicate that alemtuzumab is effective in the real-world setting in patients with different treatment histories and longer treatment duration. Study support: Sanofi.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Socioeconomic Status and MS disease severity in Chile (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_728;
Public health patients, as a proxy for SES and being diagnosed before 2016 as a proxy for high-efficacy DMT delay are independent risk factors for increased disease severity. Changes in public policies such as early diagnosis and universal access to high-efficacy DMT improve outcomes in MS.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Relapse reduction by disease-modifying therapies for relapsing multiple sclerosis: A network meta‑analysis (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_542;
Recently, several novel DMTs including ofatumumab, ozanimod, and ponesimod were approved for the treatment of RMS in the United States and/or Europe... Ofatumumab was identified as a highly effective treatment option for reducing relapse risk in patients with RMS among both contemporary and older DMTs.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Network meta-analysis of disease-modifying therapies for relapsing multiple sclerosis based on confirmed disability progression: Investigating the influence of cross-trial differences in endpoint definition (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_537;
Ofatumumab was identified as a highly effective treatment option for reducing relapse risk in patients with RMS among both contemporary and older DMTs. The definition used for progression can impact the ranking of DMTs in an NMA for this endpoint.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Prescribing trends of MS disease modifying therapies during the COVID-19 pandemic: Analysis of NHS England prescriptions and comparison with international trends (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_521;
Comparison of prescribing trends of MS DMTs in England with those from other countries highlights the interplay of different factors in altering DMT prescription practices. These observations have implications in population-based studies involving MS disease activity including the period of the COVID-19 pandemic.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Observational study of a novel peri-infusion regimen on the infusion-associated reactions with alemtuzumab in patients with MS in a Canadian clinical setting (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_505;
This protocol was associated with no serious IARs. While most pts had at least one potential vital sign abnormality, none were of clinical significance.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] A disease modifying therapy panel for multiple sclerosis: experience of the first 2 years (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_500;
The NI DMT Panel meeting has facilitated timely consideration of escalation/high efficacy therapies in a collaborative environment, allowing open review of clinical/MRI data and application of prescribing guidelines. A rolling assessment of outcomes and practices is ongoing.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Management of intravenous therapy for MS during COVID-19 pandemic (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_494;
Patient on antiCD20 therapy seems to be at higher risk from most serious Covid-19 disease. PCR is a useful tool to prevent from virus shedding at day hospital.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Blood pressure excursions with alemtuzumab in Canadian patients with relapsing remitting multiple sclerosis (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_488;
Alemtuzumab infusion was associated with a general hypotensive effect, though frequent sustained hyper- and hypotensive excursions also occurred with a peak incidence on Day 4. Hypertensive excursions were relatively rare in patients with elevated baseline SBP.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Persistence of seroprotective titers of antibodies against HBV and VZV in MS patients (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_483;
DMT’s might influence the persistence of antibodies against HBV after successful immunization; in our sample, anti-CD20 drugs were associated with an 11-fold increased risk of losing seroprotection in the first years of treatment. Long-term outcomes of VZV vaccination were not influenced by DMT treatment.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Can induction of autoimmune antibodies after alemtuzumab treatment of multiple sclerosis predict secondary autoimmunity? (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_479;
Smoking was also a risk factor of SAD. In contrast, non-thyroid auto-Abs were not helpful in predicting NTSAD.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Risk of cancer with disease-modifying drugs in multiple sclerosis: a new-user cohort design in the French nationwide claims database (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_471;
Results suggest a trend of increased risk of cancer in patients with MS who initiated IS compared with IIM. Longer follow-up of this patient population is warranted.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] COVID-19 in a neuroimmunology and multiple sclerosis referral unit (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_336;
Los datos de nuestra serie estan en concordancia con otros estudios, mostrando que la esclerosis múltiple per se y los diferentes tratamientos immunomoduladors no son un factor de riesgo para el COVID19. Es importante acelerar la vacunación de los pacientes con esclerosis múltiple para reducir la posibilidad de infección por SARS-CoV-2.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] SARS-COV-2 infection impact on patients with multiple sclerosis and neuromyelitis spectrum disorder in a Colombia cohort (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_334;
35% received Natalizumab, 19% Fingolimod, 15% Ocrelizumab, 8% Alemtuzumab, and 8% Rituximab; 15% were not receiving DMT, and 27% had received the last dose of their respective DMT in the previous 30 days[IA1] . Clinical outcomes of COVID infection in patients with MS and NMOSD did not differ from what is reported in similar studies in Latin-American population.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Basal levels of serum neurofilament light in normal aging and multiple sclerosis patients (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_291;
sNFL levels increased with aging across both in healthy control and pwMS, although it was more pronounced among PMS patients, albeit absence of disease activity and treatment. This may suggest that ongoing degeneration is largely unaffected by current treatments.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Factors contributing to CSF NfL reduction over time in people with multiple sclerosis starting treatment: an observational study (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_274;
In this small observational study of pwMS undergoing two CSF NfL measurements, factors reflecting early disease stage were associated with more pronounced drop in CSF NfL after starting immunotherapy explaining separately between 12 and 21% of the variation in CSF NfL levels. These observations suggest a stronger neuroprotective effect of such treatment when used early in the course of MS.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] micro-RNA expression profile in PBMCs changes after alemtuzumab treatment in patients with relapsing-remitting multiple sclerosis (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_252;
Pro- and anti-inflammatory miRNAs are simultaneously upregulated during the first 6 months after treatment suggesting a broad activation of monocytes as part of the reorganization process. Within 12 months this inflammatory cascade appears to subside.
- Zinbryta (daclizumab) / Biogen, AbbVie
[VIRTUAL] ECTRIMS Lecture: Gains by translation: from basic neuroimmunology to disease modifying therapies (Stream 1 Clinical) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_111;
In the 1990ies the first two treatments, interferon-beta and glatiramer-acetate, which were based on the above data, became available, and a decade later, the anti-VLA4 antibody natalizumab, which is highly effective in MS, was approved...During the last ten years several small molecules like cladribine, teriflunomide, dimethylfumarate, and several S1P receptor modulators (fingolimod, ozanimod, siponimod), and also biologics including an antibody against the lymphocyte surface marker CD52 (alemtuzumab), another against the IL-2 receptor alpha chain, (daclizumab; withdrawn) and particularly the anti-CD20 antibodies (ocrelizumab, ofatumumab), which efficiently deplete B cells and are highly effective in MS, have been approved...We will soon probably not only see the advent of therapies targeting B cell function more specifically, but hopefully also antigen-specific, neuroprotective and remyelinating therapies. The lecture will focus on particularly instructive examples of translational research.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Nursing digital care during COVID-19 outbreak: the experience of multiple sclerosis centre in southern Italy (Stream 8 Nurses' Sessions) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_103;
Thanks to the Smcare2.0 APP we found a reduction of the barriers to collect the data that provide an objective and holistic view of a patient’s clinical status. Thanks to the Smcare2.0 App we want to build an assessment tool that enables the aggregation of datasets traditionally employed in clinical trials.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Blood-brain barrier permeability changes in multiple sclerosis during alemtuzumab treatment (Stream 3 Pathogenesis) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_66;
This somewhat mirrors blood lymphocyte counts, showing a more pronounced decrease after the first course when compared to the second course. DCE-MRI has previously been found to predict treatment response, but here for the first time we report a treatment associated change in BBB permeability.
- || Lemtrada (alemtuzumab) / Sanofi
Clinical, Journal, HEOR: Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis. (Pubmed Central) - Jul 30, 2021
P3
Alemtuzumab-treated CARE-MS II patients improved or stabilized HRQL versus baseline over 6 years. This is the first study to show long-term HRQL benefits in patients with HAD.
- || Lemtrada (alemtuzumab) / Sanofi
Biomarker, Trial completion: Motor Evoked Potentials as a Biomarker in Alemtuzumab Treated Multiple Sclerosis Patients (clinicaltrials.gov) - Jul 28, 2021
P=N/A, N=10, Completed, Sponsor: Clinique Neuro-Outaouais
This is the first study to show long-term HRQL benefits in patients with HAD. Active, not recruiting --> Completed
- ||| Lemtrada (alemtuzumab) / Sanofi
Enrollment change: TOPAZ: Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409 (clinicaltrials.gov) - Jul 23, 2021
P4, N=1062, Completed, Sponsor: Genzyme, a Sanofi Company
Active, not recruiting --> Completed N=812 --> 1062
- || Lemtrada (alemtuzumab) / Sanofi
Review, Journal: Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era. (Pubmed Central) - Jul 21, 2021
Currently, three COVID-19 vaccines have been granted emergency use authorization in the USA on the basis of promising interim findings of ongoing trials. Because analyses of these vaccines in people with MS are not available, decisions regarding COVID-19 vaccination and DMT choice should be informed by data and expert consensus, and personalized with considerations for disease burden, risk of infection, and other factors.